
## Hartmut B Krentz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9499499/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Uptake Success and Cost Savings from Switching to a Two-Drug Antiretroviral Regimen. AIDS Patient Care and STDs, 2022, 36, 1-7.	2.5	2
2	Longitudinal analysis of HIV outcomes for persons living with HIV in non-urban areas in southern Alberta, Canada. Jammi, 2022, 7, 44-53.	0.5	0
3	Reporting on patients living with HIV "disengaging from care― Who is actually "lost to follow-up�. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2021, 33, 114-120.	1.2	3
4	What are the drivers of high-cost HIV patients?. International Journal of STD and AIDS, 2021, 32, 095646242110209.	1.1	1
5	Economic impact on direct healthcare costs of missing opportunities for diagnosing HIV within healthcare settings. HIV Medicine, 2021, 22, 723-731.	2.2	4
6	Evaluating medical conferences: the emerging need for a quality metric. Scientometrics, 2020, 122, 759-764.	3.0	8
7	In Defense of Baseline Genotypic Antiretroviral Resistance Testing. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, e1-e2.	2.1	2
8	Updated direct costs of medical care for HIVâ€infected patients within a regional population from 2006 to 2017. HIV Medicine, 2020, 21, 289-298.	2.2	9
9	Missed opportunities within healthcare for an earlier diagnosis of HIV. International Journal of STD and AIDS, 2020, 31, 1169-1177.	1.1	6
10	Desimplification of Single Tablet Antiretroviral (ART) Regimens—A Practical Cost-Savings Strategy?. Journal of the International Association of Providers of AIDS Care, 2019, 18, 232595821882230.	1.5	3
11	The Impact of "Churn―on Plasma HIV Burden Within a Population Under Care. Open Forum Infectious Diseases, 2019, 6, ofz203.	0.9	8
12	An approach to conference selection and evaluation: advice to avoid "predatory―conferences. Scientometrics, 2019, 118, 687-698.	3.0	14
13	Deâ€simplifying singleâ€ŧablet antiretroviral treatments: uptake, risks and cost savings. HIV Medicine, 2019, 20, 214-221.	2.2	16
14	An Emerging Concern—High Rates of Frailty among Middle-aged and Older Individuals Living with HIV. Canadian Geriatrics Journal, 2019, 22, 190-198.	1.2	9
15	Patient perspectives on deâ€simplifying their singleâ€ŧablet coâ€formulated antiretroviral therapy for societal cost savings. HIV Medicine, 2018, 19, 290-298.	2.2	8
16	Managing HIV infection in patients older than 50 years. Cmaj, 2018, 190, E1253-E1258.	2.0	12
17	Long-term HIV/AIDS survivors: Patients living with HIV infection retained in care for over 20 years. What have we learned?. International Journal of STD and AIDS, 2018, 29, 1098-1105.	1.1	6
18	Reporting on the Prevalence of Antiretroviral Drug Resistance in a Regional HIV Population over 20 Years: A Word of Caution. Antiviral Therapy, 2017, 22, 277-286.	1.0	9

HARTMUT B KRENTZ

#	Article	IF	CITATIONS
19	Healthcare contacts among patients lost to follow-up in HIV care: review of a large regional cohort utilizing electronic health records. International Journal of STD and AIDS, 2017, 28, 1275-1281.	1.1	3
20	Understanding the delay in starting antiretroviral therapy despite recent guidelines for HIV patients retained in care. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 564-569.	1.2	10
21	The Impact of Non-Antiretroviral Polypharmacy on the Continuity of Antiretroviral Therapy (ART) Among HIV Patients. AIDS Patient Care and STDs, 2016, 30, 11-17.	2.5	43
22	Maintaining the continuity of HIV-care records for patients transferring care between centers: challenges, workloads, needs and risks. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 1073-1078.	1.2	5
23	Mortality in migrants with HIV in western Europe. Lancet HIV,the, 2015, 2, e508-e509.	4.7	0
24	The Impact of Transfer Patients on the Local Cascade of HIV Care Continuum. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 236-240.	2.1	3
25	Patient Perspectives on Leaving, Disengaging, and Returning to HIV Care. AIDS Patient Care and STDs, 2015, 29, 400-407.	2.5	14
26	Increased costs of <scp>HIV</scp> care associated with aging in an <scp>HIV</scp> â€infected population. HIV Medicine, 2015, 16, 38-47.	2.2	35
27	The Cost of Antiretroviral Drug Resistance in HIV-Positive Patients. Antiviral Therapy, 2014, 19, 341-348.	1.0	14
28	High Mortality Among Human Immunodeficiency Virus (HIV)-Infected Individuals Before Accessing or Linking to HIV Care: A Missing Outcome in the Cascade of Care?. Open Forum Infectious Diseases, 2014, 1, ofu011.	0.9	11
29	The Clinical Implications of High Rates of Intimate Partner Violence Against HIV-Positive Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, 32-38.	2.1	62
30	The Effect of Churn on "Community Viral Load―in a Well-Defined Regional Population. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 64, 190-196.	2.1	12
31	Prevalence, clinical associations, and impact of intimate partner violence among <scp>HIV</scp> â€infected gay and bisexual men: a populationâ€based study. HIV Medicine, 2013, 14, 293-302.	2.2	48
32	Retention Among North American HIV-Infected Persons in Clinical Care, 2000–2008. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 356-362. The Direct Medical Costs of Late Presentation Communication (1910), 10,784314 reBT/Overlock 10 Tf 50 202 Tc	2.1   (xmlns:m	131 ml="http://w
33		0.7	65
34	15-Year Period. AIDS Research and Treatment, 2012, 2012, 1-8. Pill Burden in HIV Infection: 20 Years of Experience. Antiviral Therapy, 2012, 17, 833-840.	1.0	45
35	Comparison of healthcare costs between local and immigrant HIV populations living in Southern Alberta, Canada. Health Policy, 2011, 103, 124-129.	3.0	7
36	Adverse Health Effects for Individuals Who Move Between HIV Care Centers. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 51-54.	2.1	15

HARTMUT B KRENTZ

#	Article	IF	CITATIONS
37	Despite CD4 cell count rebound the higher initial costs of medical care for HIV-infected patients persist 5 years after presentation with CD4 cell counts less than 350 μl. Aids, 2010, 24, 2750-2753.	2.2	29
38	The five-year impact of an evolving global epidemic, changing migration patterns, and policy changes in a regional Canadian HIV population. Health Policy, 2009, 90, 296-302.	3.0	25
39	Cost of medical care for HIVâ€infected patients within a regional population from 1997 to 2006. HIV Medicine, 2008, 9, 721-730.	2.2	52
40	Longitudinal assessment (1995–2003) of hospitalizations of HIV-infected patients within a geographical population in Canada. HIV Medicine, 2006, 7, 457-466.	2.2	51
41	Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Medicine, 2005, 6, 99-106.	2.2	186
42	Impact of Practice Changes on an Antiretroviral Budget in an HIV Care Program. Disease Management and Health Outcomes, 2005, 13, 209-217.	0.4	9
43	The high cost of medical care for patients who present late (CD4<200 cells/muL) with HIV infection. HIV Medicine, 2004, 5, 93-98.	2.2	236
44	The impact on health-related quality of life of treatment interruptions in HIV-1-infected patients. Aids, 2003, 17, 631-633.	2.2	15
45	The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001. Cmaj, 2003, 169, 106-10.	2.0	21